Back to all assets

Solventum SOLV

equity

Price History

$52.88$63.73$74.59$85.44
2024-03 · DCA start$69.55

Time underwater

How far below its previous all-time high the price sat, each month. 0% means a new high.

-24.0%-16.0%-8.0%0.0%
2024-032026-08 · -0.2%

Worst drawdown: −24%, peaking Mar 2024 and bottoming Jun 2024 — 6 months below the prior high before recovering.

DCA Backtest

Invested
$3,000
Value today
$3,609
Return
+20.3%
Months invested
30

Scenarios

Inflation — the same contributions merely keeping pace with CPI would be $3,103 today, so the real (inflation-adjusted) return is +16.3%.

Lump sum instead — $3,000 all at once in Mar 2024: $3,679 (+22.6%) — lump sum came out ahead.

Worst timing — same monthly amount started at the all-time high (Jul 2026): $199.82 on $200 invested (-0.1%).

⚠ Price returns only — dividends are not included. This understates the true return of dividend-paying shares, and any comparison against crypto (which pays no dividends) is biased against equities by roughly the dividend yield, compounded.

If this saved you a spreadsheet — buy me a coffee.

Every start month at once

Each cell is the return-to-date of £/$/€100-a-month DCA started that month. Click a cell to load it in the backtest above. The ringed cell is the all-time-high start — the worst timing scenario.

JFMAMJJASOND
2024
2025
2026
Legend:−50%−20%0%+50%+200%+1000%worst timing (ATH)Selected 2024-03: +20.3%

About Solventum

Solventum Corporation is an American health care company that was spun off from 3M on April 1, 2024. (Wikipedia)

It's a listed company categorised under health care and health care technology, with a market cap of about $14.5B.

It rates High Risk at 2.8/5, meaning several rated factors score badly, so this carries materially more risk than a typical holding.

What pushes the score up: earnings quality (5.0/5) and leverage / financial (3.0/5).

Scoring well: liquidity at 1.0/5.

Not yet researched: concentration, governance. These are excluded from the score rather than guessed, so the real risk may be higher than what’s shown.

Ratings summarise sourced facts against fixed rules — not investment advice, and no substitute for your own diligence.

Risk Profile

High Risk(2.8/5)80% rated

How these ratings work

Market / Volatility2.0/5 · weight 20%
  • Annualised volatility (3yr)3/530.0
  • Max drawdown from ATH1/524.0
  • Beta vs S&P 5002/50.71
Liquidity1.0/5 · weight 15%
  • Avg daily $ volume1/5131.2m
  • Float % of shares outstandingnot yet researched
Leverage / Financial3.0/5 · weight 20%
  • Debt / equity3/51.1
  • Interest coverage (EBIT / interest)not yet researched
Earnings Quality5.0/5 · weight 15%
  • 3yr EPS volatility5/5202
Concentrationunrated · weight 10%
  • Largest customer, % of revenuenot yet researched
  • Geographic revenue concentrationnot yet researched
Governanceunrated · weight 10%
  • Board independence %not yet researched
  • Share structurenot yet researched
  • Litigation / audit historynot yet researched
Sector / Regulatory3.0/5 · weight 10%
  • Sector regulatory exposure3/5elevated

Linked Assets

Same sector, or return-correlated — worth knowing what else might move if this one does.